Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma

The long-term survival of patients with advanced urothelial carcinoma (UCa) is limited because of innate resistance to treatment. We identified elevated expression of the histone methyltransferase EZH2 as a hallmark of aggressive UCa and hypothesized that EZH2 inhibition, via a small-molecule catalytic inhibitor, might have antitumor effects in UCa. Here, in a carcinogen-induced mouse bladder cancer model, a reduction in tumor progression and an increase in immune infiltration upon EZH2 inhibition were observed. Treatment of mice with EZH2i causes an increase in MHC class II expression in the urothelium and can activate infiltrating T cells. Unexpectedly, we found that the lack of an intact adaptive immune system completely abolishes the antitumor effects induced by EZH2 catalytic inhibition. These findings show that immune evasion is the only important determinant for the efficacy of EZH2 catalytic inhibition treatment in a UCa model.

[1]  M. Corazzari,et al.  Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids , 2021, International journal of molecular sciences.

[2]  A. Shilatifard,et al.  The roles of Polycomb repressive complexes in mammalian development and cancer , 2021, Nature Reviews Molecular Cell Biology.

[3]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[4]  M. Glickman,et al.  Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling , 2020, Proceedings of the National Academy of Sciences.

[5]  Mauro A. A. Castro,et al.  Identification of Differential Tumor Subtypes of T1 Bladder Cancer. , 2020, European urology.

[6]  D. Bajorin,et al.  Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) , 2020 .

[7]  M. Galsky,et al.  Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[8]  P. Crispen,et al.  Mechanisms of immune evasion in bladder cancer , 2019, Cancer Immunology, Immunotherapy.

[9]  R. Tothill,et al.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer , 2019, Cancer cell.

[10]  P. Robson,et al.  Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma , 2019, bioRxiv.

[11]  Jan Baumbach,et al.  Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..

[12]  Yanni Yu,et al.  Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors. , 2019, Journal of visualized experiments : JoVE.

[13]  Q. Hu,et al.  Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer , 2019, Cell Death & Differentiation.

[14]  Gary D Bader,et al.  Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap , 2019, Nature Protocols.

[15]  Douglas B. Johnson,et al.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer , 2018, Clinical Cancer Research.

[16]  L. Dyrskjøt,et al.  Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology , 2018, Current opinion in urology.

[17]  J. Witjes,et al.  Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. , 2018, European urology.

[18]  A. Shilatifard,et al.  A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer , 2017, Oncogene.

[19]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[20]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[21]  O. Boyman,et al.  The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. , 2017, Cell reports.

[22]  D. Speiser,et al.  Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data , 2017, bioRxiv.

[23]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.

[24]  Swe Swe Myint,et al.  Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2 , 2017, Science Translational Medicine.

[25]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[26]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[27]  K. Helin,et al.  Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. , 2016, Cold Spring Harbor perspectives in medicine.

[28]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[29]  A. Shilatifard,et al.  Epigenetic balance of gene expression by Polycomb and COMPASS families , 2016, Science.

[30]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[31]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[32]  Y. Dou,et al.  PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. , 2016, Cancer research.

[33]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[34]  Kathleen R. Cho,et al.  Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.

[35]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[36]  R. Brosch,et al.  Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. , 2014, European urology.

[37]  P. Beachy,et al.  Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma , 2014, Nature Cell Biology.

[38]  K. Helin,et al.  Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication , 2014, Nature Communications.

[39]  Shih-Ming Huang,et al.  Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo , 2014, Oncotarget.

[40]  J. Sage,et al.  Molecular and Cellular Pathobiology In Vivo Disruption of an Rb – E 2 F – Ezh 2 Signaling Loop Causes Bladder Cancer , 2014 .

[41]  Mark W. Ball,et al.  Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. , 2012, Urologic oncology.

[42]  M. Albert,et al.  Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.

[43]  Nathaniel H. Boyd,et al.  Early epigenetic events regulate the adaptive immune response gene CIITA , 2011, Epigenetics.

[44]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[45]  H. Pasolli,et al.  EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. , 2011, Genes & development.

[46]  D. Pasini,et al.  Epigenetic factors in cancer development: polycomb group proteins. , 2011, Future oncology.

[47]  K. Miller,et al.  Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder , 2008, Journal of Cancer Research and Clinical Oncology.

[48]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[49]  Yi Luo,et al.  Urinary Bladder Epithelium Antigen Induces CD8+ T Cell Tolerance, Activation, and Autoimmune Response1 , 2007, The Journal of Immunology.

[50]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[51]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.